Skip to main content
OpenTrials
Completed

NCT Number: NCT03283358

Person-centered Follow up and Health Promotion Program After Revascularization for Intermittent Claudication

The overall aim of the study is to evaluate a nurse-led intervention (person-centered follow up and health promotion) program in comparison to standard follow up for patients treated with surgical or endovascular revascularization of Intermittent Claudication.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Surgery, Unit of Vascular Surgery, Södersjukhuset, Stockholm, Sweden

Loading trial locations.

About this study

Specific Aims:

  • To evaluate the effect of the intervention program on patient's adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents), risk modification and surgical treatment outcomes
  • To investigate the effect of the intervention program on patient reported outcomes
  • To investigate the effect of the intervention program on patient reported experiences
  • To investigate the long-term effect of the intervention program on mortality, cause of death, occurrence/recurrence of cardiovascular disease up to 10 years after the surgical/endovascular treatment
  • To compare patient-reported adherence to medication and patient data registry adherence to medication

Hypothesis: Participants in the Intervention Group have better adherence to prescribed medication and a reduced risk for 10-year predicted coronary heart disease (CHD) compared to participants in the Control Group.

Study population:

Patients with Intermittent Claudication scheduled for revascularization, through open surgery or endovascular method, in Stockholm will be screened for inclusion. After informed consent, the participants will be randomized to either Intervention Group or Control Group. Those participants who couldn't receive revascularization after giving consent will be withdrawn from the study and counted as drop outs. Power analysis has showed a required sample size of 186 participants to detect a statistically significant increase in adherence to medication from 50% to 70% (power 0.80, significance value 0.05, two-sided). Expecting 10% drop-out we plan to recruit 210 participants.

Data collection:

Data on primary and secondary outcomes, serum cholesterol, smoking status, serum carbon monoxide, Hba1c, BMI, waist circumference, physical exercise, diet, alcohol consumption, graft patency, re-intervention, hospitalization during the study year, mortality and patient characteristics/demographics will be collected at baseline and one year after treatment. All data will be registered at a local research data base at Karolinska Institutet. All patient-reported outcomes will be collected using web-based questionnaires linked to the data base.

Data analysis:

Comparisons between the Intervention Group and the Control Group will be made using t-test and ANOVA for repeated-measures or Wilcoxon rank-signed test and Kruskall-Wallis according to the underlying distribution for continuous data, and Fischers Exact test for categorical data. Logistic regression analysis will also be performed to adjust for confounding factors. All analyses will be performed according to the Intention-to-treat principle.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients who is scheduled for revascularization, through open and/or endovascular surgery for IC diagnosed according to Diagnosis Related Group (DRG) with I70.2 or I739B

Exclusion criteria

  • Patients not treated through surgery or revascularization
  • Patients diagnosed with dementia
  • Patients discharge to a nursery home,
  • Patients not accountable for administrating their own medications
  • Patients with a survival expectancy less than one year

Treatment and study plan

Person-centered follow up

Behavioral

Primary outcomes

  1. Adherence to medication

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents) according to the Swedish Prescribed Drug Registry (PDR). dispensed anticoagulant agents, antiplatelet agents (ATC-register B01A) and lipid-lowering agents (ATC-register C10). Those participants who have fetched both medications for the second refill after treatment will be considered adherent.

Secondary outcomes

  1. Risk for 10-year predicted coronary heart disease (CHD)

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Changes in risk for CHD within 10-years measured by Framingham Risk Score (FRHS).

Other outcomes

  1. Patient reported adherence to medication

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-reported adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents).

  2. Generic Health-related Quality of Life (HRQOL)

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-reported generic HrQoL measured by EQ-5D

  3. Condition specific Health-related Quality of Life (HRQOL)

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-reported specific HrQoL measured by VascQol-6

  4. Beliefs on medication

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-reported beliefs on medication measured by Beliefs about Meicines Questionnaire (BMQ)

  5. Self-efficacy

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-reported Self-efficacy measured by Swedish Version of the General Self-Efficacy Scale

  6. Health literacy

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-reported health literacy measured by HLS-EU-Q16 SE

  7. Patient-experienced quality of care

    Time frame: One year after surgical or endovascular treatment for Intermittent Claudication

    Patient-experienced quality of care measured by Quality of Care from Patient's Perspective (Swedish version of QPP)

  8. Mortality

    Time frame: Ten years after surgical or endovascular treatment for Intermittent Claudication

    Data on mortality will be extracted from the National Patient Registry and Stockholm County Council's administrative data (VårdanalysdataLager - VAL).

  9. Cardiovascular disease

    Time frame: Ten years after surgical or endovascular treatment for Intermittent Claudication

    Data on occurrence/reoccurrence of cardiovascular disease with hospitalization will be extracted from the National Patient Registry and Stockholm County Council's administrative data (VårdanalysdataLager - VAL).

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Acronym: FASTIC

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Sep 14, 2017
Registry last updated
Oct 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.